WebMar 1, 2024 · Feb 28 (Reuters) - Cytokinetics Inc (CYTK.O) said on Tuesday the U.S health regulator declined to approve its oral drug for a type of heart failure, citing lack of … WebApr 3, 2024 · Cytokinetics is also looking to begin two more Phase III trials for aficamten this year, Blum said. The candidate cleared Phase II and showed it could significantly cut the average resting left ventricular outflow tract pressure gradient in the REDWOOD-HCM study. The FDA gave aficamten its Breakthrough Therapy designation in December 2024.
Cytokinetics Provides Regulatory Update Related to New Drug
WebFDA认为该公司递交的NDA不完整,无法进行实质性审查。受此消息影响,Soligenix公司股价暴跌约40%。 Cytokinetics . 2月28日,细胞动力学公司(Cytokinetics)宣布,已收到FDA发布的一份关于omecamtiv mecarbil用于治疗射血分数降低的心力衰竭(HFrEF)新药申请的完整回复函。 WebJun 24, 2024 · SOUTH SAN FRANCISCO, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and … grammar checking online
FDA staff reviewers flag safety concerns over Cytokinetics
WebDec 9, 2024 · Cytokinetics Inc Follow U.S. Food and Drug Administration Dec 9 (Reuters) - U.S. Food and Drug Administration staff reviewers on Friday identified safety and efficacy concerns about... WebApr 9, 2024 · FDA Approves Lecanemab for the Treatment for Alzheimer Disease. On January 6, 2024, the FDA approved the first novel drug of 2024, with a nod to lecanemab-irmb (Leqembi) for the treatment of Alzheimer’s disease. Approved through the FDA’s accelerated approval pathway based on the results of the phase 3 Clarity AD trial, the … WebAficamten was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten was designed to reduce the hypercontractility associated with HCM. grammar checking free online